Vancouver, British Columbia–(Newsfile Corp. – February 22, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTC: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced ethics approval for an upcoming pre-clinical study to be conducted by the clinical research organization, Science in Action…
